LAUREN LEGRAND: Open Payments
NPI 1851938807 · GLASGOW, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$753 in 34 payments from 13 companies in 2025. Trend: 2023 $576 · 2024 $738 · 2025 $753
Food & beverage: $753
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 5 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $97 |
| AstraZeneca Pharmaceuticals LP | 4 | $85 |
| Daiichi Sankyo Inc. | 3 | $79 |
| ABBVIE INC. | 4 | $78 |
| Merck Sharp & Dohme LLC | 4 | $75 |
| Genentech USA, Inc. | 3 | $56 |
| Novartis Pharmaceuticals Corporation | 2 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Celgene Corporation | 1 | $22 |
Products named: IBRANCE, KEYTRUDA, TAGRISSO, FRUZAQLA, DATROWAY, PLUVICTO, VENCLEXTA, XTANDI.
Industry payments across KY — which companies pay providers there.
